Payment overview · 2025
General Payments
$18.07
1 reported records · 1 companies
Healthcare provider profile · identity verified
Il Jun Chon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EPHRATA, PA · NPI 1538173869
Verified facts
What the public records show
CMS Open Payments records show Il Jun Chon, M.D. received $18.07 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.07 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.07 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 226 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 218 | 63 |
| Lisinopril | Lisinopril | 176 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 47 |
| Losartan Potassium | Losartan Potassium | 173 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 169 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 29 |
| Gabapentin | Gabapentin | 106 | 26 |
| Eliquis | Apixaban | 99 | 30 |
| Metformin Hcl | Metformin Hcl | 99 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 33 |
| Simvastatin | Simvastatin | 97 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 23 |
| Ozempic | Semaglutide | 93 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 29 |
| Sertraline Hcl | Sertraline Hcl | 81 | 19 |
| Famotidine | Famotidine | 79 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 20 |
| Furosemide | Furosemide | 63 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 20 |
| Trazodone Hcl | Trazodone Hcl | 61 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 14 |
| Metformin Hcl Er | Metformin Hcl | 52 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 20 |
| Meloxicam | Meloxicam | 51 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 12 |
| Jardiance | Empagliflozin | 50 | 17 |
| Baclofen | Baclofen | 48 | suppressed |
| Glipizide Er | Glipizide | 47 | 13 |
| Azithromycin | Azithromycin | 46 | 40 |
| Potassium Chloride | Potassium Chloride | 45 | 18 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 11 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Torsemide | Torsemide | 30 | 17 |
| Tramadol Hcl | Tramadol Hcl | 30 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 14 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Prednisone | Prednisone | 28 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 19 |
| Topiramate | Topiramate | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 21 | 19 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | 11 |
| Primidone | Primidone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.07 · 1 records | Novo Nordisk Inc | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error